Publications by authors named "A H M Willemsen"

The need for high-quality protist genomes has prevented in-depth computational and experimental studies of giant virus-host interactions. In addition, our current knowledge of host range is highly biased due to the few hosts used to isolate novel giant viruses. This study presents 6 high-quality amoeba genomes from known and potential giant virus hosts belonging to 2 distinct eukaryotic clades: Amoebozoa and Discoba.

View Article and Find Full Text PDF

Health Technology Assessment (HTA) in Europe has undergone significant evolution, culminating in the adoption of Regulation (EU) 2021/2282 on HTA (HTAR) aimed at fostering sustainable collaboration in HTA at the European Union (EU) level. The EUnetHTA 21 project, a 2-year initiative, was commissioned to address key methodological issues and prepare for the implementation of the HTAR. This commentary documents the outcomes of the EUnetHTA 21 project, focusing on Joint Clinical Assessments (JCAs), while analyzing challenges encountered and lessons learned for future collaboration under the HTAR.

View Article and Find Full Text PDF
Article Synopsis
  • The study evaluates a new meningococcal vaccine (MenABCWY) that combines components of the existing MenB vaccine (4CMenB) and the MenACWY vaccine, aiming to provide broad immunization against various meningococcal strains and ease vaccination schedules.
  • Conducted as a phase 3 randomized trial across multiple countries, healthy participants aged 10-25 were assigned to receive different vaccine schedules to assess safety, immune response, and consistency of vaccine lots.
  • The trial primarily focused on the immune response to MenB strains, comparing MenABCWY's effectiveness to 4CMenB and evaluating the consistency of immune responses among different production lots of the vaccines.
View Article and Find Full Text PDF

Background: Managing risk effectively within small animal veterinary practice is integral for staff, patient and client safety. Veterinary personnel are exposed to many risks, including bites, scratches, sharps injuries and exposure to zoonotic diseases and multi-resistant organisms. Patients may also be exposed to healthcare-associated infections, including multi-resistant organisms.

View Article and Find Full Text PDF
Article Synopsis
  • Meningococcal serogroup B (MenB) vaccination with the 4CMenB vaccine was tested for its effectiveness and safety among 3,651 healthy participants aged 10 to 25, using different dosing schedules (0-2, 0-6, and 0-2-6 months).
  • The study measured the immune response through two methods: a test-based approach showing high immune breadth (over 78%) and a responder-based approach indicating a significant percentage of participants achieved strong responses (up to 93.4% for the 0-2-6 schedule).
  • The results showed no major differences in effectiveness across the dosing schedules, confirming that the simpler 2-dose regimen (0-2)
View Article and Find Full Text PDF